Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPI-1005 in moderate COVID-19
NCT04484025Phase 2Enrolling by invitation
- Sponsor
- Sound Pharmaceuticals
- Start
- Oct 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ebselen in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Sound Pharmaceuticals. Primary endpoint: Number of participants with treatment-related adverse events at 30 days. Started Oct 2021; status: enrolling by invitation.
02
Drugs
ebselen
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04484025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04484025.